Benitec grants license in Ambion settlement
Tuesday, 10 August, 2004
Benitec (ASX: BLT) has settled its patent infringement case against US company Ambion, giving the company a world-wide non-exclusive licence to make and sell DNA-directed RNAi products.
The suit, which was originally filed on March 22, 2004 in the US, was settled out of court. Details of the settlement and licence have not been released by the company.
The Ambion suit was first announced in March, along with two other lawsuits filed against Nucleonics and Genscript Corporation.
"We will continue to protect our issued RNAi patent estate whilst enabling the widest usage of this important technology for both research and commercial therapeutic purposes," said CEO John McKinley in a statement.
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
